Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$40.00 USD
0.00 (0.00%)
Updated Sep 20, 2024 03:53 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Calliditas Therapeutics AB Sponsored ADR (CALT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$35.50 | $40.00 | $17.00 | -11.25% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Calliditas Therapeutics AB Sponsored ADR comes to $35.50. The forecasts range from a low of $17.00 to a high of $40.00. The average price target represents a decline of 11.25% from the last closing price of $40.00.
Analyst Price Targets (6 )
Broker Rating
Calliditas Therapeutics AB Sponsored ADR currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on six recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/31/2024 | Not Identified | Not Identified | Strong Buy | Hold |
5/28/2024 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Hold |
5/28/2024 | Not Identified | Not Identified | Strong Buy | Hold |
5/28/2024 | Not Identified | Not Identified | Strong Buy | Hold |
2/21/2024 | Guggenheim Securities | Vamil Divan | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 5 |
Average Target Price | $35.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 253 |
Current Quarter EPS Est: | -0.05 |
CALT FAQs
Calliditas Therapeutics AB Sponsored ADR (CALT) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Calliditas Therapeutics AB Sponsored ADR (CALT) is $35.50. The current on short-term price targets is based on 2 reports.
The forecasts for Calliditas Therapeutics AB Sponsored ADR (CALT) range from a low of $17 to a high of $40. The average price target represents a decline of $11.25 from the last closing price of $40.00.
The current DOWNSIDE for Calliditas Therapeutics AB Sponsored ADR (CALT) is 11.25%
Based on short-term price targets offered by six analysts, the average price target for Calliditas Therapeutics AB Sponsored ADR comes to $35.50. The forecasts range from a low of $17.00 to a high of $40.00. The average price target represents a decline of 11.25% from the last closing price of $40.00.